On Friday, Wells Fargo adjusted its outlook on Health Catalyst Inc. (NASDAQ: NASDAQ:HCAT), reducing the stock price target to $13 from $14 while retaining an Overweight rating. The revision comes in light of news that Health Catalyst's client, Steward Health, is currently undergoing bankruptcy proceedings. The timeline for resolution remains uncertain, with possibilities ranging from a few months to an extension into 2025.
Health Catalyst anticipates maintaining its relationship with Steward Health post-bankruptcy, expecting its services will continue to be integral to Steward's operations, potentially under new ownership. Despite the ongoing bankruptcy, Health Catalyst has made provisions as an unsecured creditor for the potential inability to collect pre-petitioned amounts owed by Steward Health.
The financial impact of Steward Health's bankruptcy on Health Catalyst is limited, as Steward accounts for less than 2% of the company's revenue. The estimated exposure is no more than $5 million, which includes a combination of technology and services.
The stock price target adjustment reflects the current challenges faced by Health Catalyst due to its client's financial difficulties. Still, the company's overall outlook remains positive as indicated by the maintained Overweight rating. Health Catalyst's expectation to continue its role as a key service provider post-bankruptcy suggests confidence in its business model and client retention strategy.
InvestingPro Insights
As Health Catalyst Inc. (NASDAQ: HCAT) navigates the complexities surrounding Steward Health's bankruptcy, the financial outlook and company fundamentals become even more critical for investors.
According to real-time data from InvestingPro, Health Catalyst holds a market cap of $393.75 million and has shown a revenue growth of 7.13% over the last twelve months as of Q4 2023. Despite a challenging period, the company has a positive revenue growth rate quarterly, marked at 8.56% for Q1 2023. These figures suggest that Health Catalyst is maintaining a trajectory of growth in terms of revenue.
From an operational standpoint, Health Catalyst's gross profit margin stands at 45.56%, which is a strong indicator of the company's ability to manage its cost of goods sold effectively. Yet, the company has reported an operating income margin of -29.38%, reflecting the expenses and investments made towards sustaining and growing the business.
InvestingPro Tips highlight several optimistic points for Health Catalyst. The company holds more cash than debt, which is a solid indicator of financial health and could provide a cushion during uncertain times. Analysts have also revised their earnings upwards for the upcoming period, which could be a sign of confidence in the company's future performance.
There are 5 additional InvestingPro Tips available, providing deeper insights for investors considering Health Catalyst as part of their portfolio. For those interested in accessing these valuable tips, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Overall, while the situation with Steward Health poses challenges, Health Catalyst's financial health and market position, as reflected in the provided metrics and tips, may offer reassurance to investors about the company's resilience and potential for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.